percutaneous

Bivalirudin (BG-8967) 是一种直接凝血酶(thrombin)抑制剂，是一种肽类抗凝剂，可在侵入性心脏病，特别是在经皮冠状动脉介入中用于抗凝。

Prasugrel (CS-747) 是一种噻吩吡啶和前药，是一种可口服的 P2Y12受体拮抗剂，抑制 ADP 诱导的血小板聚集，用于预防急性冠状动脉综合征患者的血栓形成、不稳定型心绞痛和心肌梗塞，以及接受经皮冠状动脉介入治疗的患者。

Laurocapram (N-Lauryl caprolactam) 是吸收促进剂，对于亲脂性和亲水性物质都是一种最有效的吸收剂。

trans-Cyclohexane-1,2-diol (trans-1,2-Cyclohexanediol) 是内源性代谢产物的一种。

Enoxaparin sodium 是一种低分子量肝素 (LMWH)，已获得美国 FDA 批准，可用于医疗管理的 ST 段心肌梗死 (STEMI) 或 STEMI 及随后的经皮冠状动脉介入治疗 (PCI) 患者。它与抗凝血酶结合并增强其作用，并抑制凝血因子 XIa、IXa、Xa 和 IIa（凝血酶），从而防止血栓形成。

C16 Phytoceramide (t18:0/16:0) is a phytoceramide, which is a family of sphingolipids found in the intestine, kidney, and extracellular spaces of the stratum corneum of the mammalian epidermis. C16 Phytoceramide (t18:0/16:0) is composed of a phytosphingosine backbone amine-linked to a C16 fatty acid chain. The levels of C16 phytoceramide (t18:0/16:0) increase following heat stress in S. cerevisiae. It has been used with other ceramides to create stratum corneum substitutes to study percutaneous penetration and psoriasis in vitro.

C24 Phytosphingosine (t18:0/24:0) is a phytoceramide, which is a family of sphingolipids found in the intestine, kidney, and extracellular spaces of the stratum corneum of the mammalian epidermis. C24 Phytosphingosine (t18:0/24:0) is composed of a phytosphingosine backbone amine-linked to a C24 fatty acid chain. It has been used with other ceramides to create stratum corneum substitutes to study percutaneous penetration and psoriasis in vitro. In a stratum corneum model of healthy skin, the incorporation of long-chain-containing phytoceramides, such as C24 phytosphingosine (t18:0/24:0), increases permeability of the membrane in comparison with incorporation of dihydroceramides.

Ciprostene (free base) is a synthetic, chemically stable analog of prostacyclin (PGI2). In animal models, administration of ciprostene resulted in dose-dependent hypotension, tachycardia, and inhibition of ex vivo ADP-induced platelet aggregation. Ciprostene was evaluated in clinical trials in patients with peripheral vascular disease. It was found to reduce restenosis in patients with coronary artery disease undergoing therapeutic percutaneous transluminal coronary angioplasty.